Tejara Capital Ltd Reduces Position in Coherus BioSciences, Inc. (NASDAQ:CHRS)

Tejara Capital Ltd trimmed its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 23.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 738,158 shares of the biotechnology company’s stock after selling 220,206 shares during the quarter. Tejara Capital Ltd owned 0.64% of Coherus BioSciences worth $1,019,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Systematic Financial Management LP purchased a new stake in shares of Coherus BioSciences during the third quarter worth about $28,000. Steph & Co. purchased a new stake in shares of Coherus BioSciences during the fourth quarter worth about $34,000. Ieq Capital LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter worth about $68,000. Savant Capital LLC purchased a new stake in shares of Coherus BioSciences during the fourth quarter worth about $130,000. Finally, FMR LLC grew its stake in Coherus BioSciences by 21.1% in the third quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 39,204 shares in the last quarter. 72.82% of the stock is owned by hedge funds and other institutional investors.

Coherus BioSciences Stock Down 0.5 %

Shares of CHRS stock opened at $0.92 on Tuesday. The business has a 50 day moving average of $1.19 and a two-hundred day moving average of $1.17. Coherus BioSciences, Inc. has a 52 week low of $0.66 and a 52 week high of $2.64. The company has a market cap of $106.12 million, a P/E ratio of -11.45 and a beta of 0.92.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on CHRS shares. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Coherus BioSciences in a research note on Tuesday, March 11th. Robert W. Baird lifted their price target on Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a research note on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.38.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.